BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30216543)

  • 1. Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease.
    Löhle M; Mangone G; Wolz M; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Corvol JC; Storch A
    Mov Disord; 2018 Sep; 33(9):1496-1501. PubMed ID: 30216543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications.
    Löhle M; Mende J; Wolz M; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Storch A
    Neurology; 2016 Jan; 86(3):231-40. PubMed ID: 26718573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putaminal Dopamine Turnover in de novo Parkinson's Disease Predicts Later Neuropsychiatric Fluctuations but Not Other Major Health Outcomes.
    Löhle M; Hermann W; Hausbrand D; Wolz M; Mende J; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Hermann A; Storch A
    J Parkinsons Dis; 2019; 9(4):693-704. PubMed ID: 31381528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional
    Löhle M; Mangone G; Hermann W; Hausbrand D; Wolz M; Mende J; Reichmann H; Hermann A; Corvol JC; Storch A
    Parkinsons Dis; 2022; 2022():5597503. PubMed ID: 35096365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
    Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
    Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
    Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
    Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study.
    Wu K; O'Keeffe D; Politis M; O'Keeffe GC; Robbins TW; Bose SK; Brooks DJ; Piccini P; Barker RA
    Brain; 2012 Aug; 135(Pt 8):2449-57. PubMed ID: 22843413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of monoamine oxidase B and catechol-O-methyltransferase polymorphisms with sporadic Parkinson's disease in an Iranian population.
    Torkaman-Boutorabi A; Ali Shahidi G; Choopani S; Reza Zarrindast M
    Folia Neuropathol; 2012; 50(4):382-9. PubMed ID: 23319194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease.
    Lynch DR; Mozley PD; Sokol S; Maas NM; Balcer LJ; Siderowf AD
    Mov Disord; 2003 Jul; 18(7):804-12. PubMed ID: 12815660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olfactory dysfunction correlates with putaminal dopamine turnover in early de novo Parkinson's disease.
    Löhle M; Wolz M; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Storch A
    J Neural Transm (Vienna); 2020 Jan; 127(1):9-16. PubMed ID: 31863171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability and validity of polymorphism association studies in Parkinson's disease.
    Tan EK; Khajavi M; Thornby JI; Nagamitsu S; Jankovic J; Ashizawa T
    Neurology; 2000 Aug; 55(4):533-8. PubMed ID: 10953187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
    Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
    J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese.
    Wu RM; Cheng CW; Chen KH; Lu SL; Shan DE; Ho YF; Chern HD
    Neurology; 2001 Feb; 56(3):375-82. PubMed ID: 11171904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease.
    Mellick GD; Buchanan DD; McCann SJ; James KM; Johnson AG; Davis DR; Liyou N; Chan D; Le Couteur DG
    Mov Disord; 1999 Mar; 14(2):219-24. PubMed ID: 10091612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis on relationship of MAOB intron 13 polymorphisms, interactions with smoking/COMT H158L polymorphisms with the risk of PD.
    Zhang Y; Piao X; Wu J; Li Y; Liang Q
    Int J Neurosci; 2016; 126(5):400-7. PubMed ID: 26000819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population.
    Białecka M; Droździk M; Honczarenko K; Gawrońska-Szklarz B; Stankiewicz J; Dabrowska E; Kubisiak M; Kłodowska-Duda G; Opala G
    Eur Neurol; 2005; 53(2):68-73. PubMed ID: 15753616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of the association between early adversity and obsessive-compulsive disorder by polymorphisms in the MAOA, MAOB and COMT genes.
    McGregor NW; Hemmings SMJ; Erdman L; Calmarza-Font I; Stein DJ; Lochner C
    Psychiatry Res; 2016 Dec; 246():527-532. PubMed ID: 27821364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Single Nucleotide Polymorphisms of Monoamine Oxidase B, Dopamine D2 Receptor, and DOPA Decarboxylase Receptors Among Patients Treated for Parkinson's Disease.
    Zapała B; Stefura T; Piwowar M; Czekalska S; Zawada M; Hadasik M; Solnica B; Rudzińska-Bar M
    J Mol Neurosci; 2022 Apr; 72(4):812-819. PubMed ID: 35044623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of COMT H108L, MAOB int 13 A>G and DRD2 haplotype on the susceptibility to Parkinson's disease in South Indian subjects.
    Kumudini N; Umai A; Devi YP; Naushad SM; Mridula R; Borgohain R; Kutala VK
    Indian J Biochem Biophys; 2013 Oct; 50(5):436-41. PubMed ID: 24772965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.